Back to News
Market Impact: 0.3
FDA Accepts BLA For Formycon And Zydus' Keytruda Biosimilar FYB206 ;Shares Rise
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
The FDA accepted for review the Biologics License Application for FYB206, a biosimilar candidate developed jointly by Formycon AG and Zydus Lifesciences. Acceptance advances the application to regulatory review but does not indicate approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
FYB0.60
More News
- US fines Bank of America $1.2bn for money laundering, sanctions violations
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Why is Bank of America stock sliding today?
- More Republicans come out against Trump's diesel deal with Putin
- Apple’s new home devices are a bet on its upgraded Siri AI
- BofA fined $1.2 billion by US government for failing to police suspicious activity
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can ChatGPT or Claude Replace a Research Platform?
- How the 2026 Milan-Cortina Winter Olympics Will Reshape Company Revenues and Stock Performance